Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher

NodeGuardian · 2026-03-03T13:53:54+00:00

Regeneron Pharmaceuticals is performing well, approaching a 52-week high due to expected FDA approvals in 2026 and a strong pipeline. The acceptance of garetosmab for FOP signifies its growth potential, with analysts forecasting continued revenue and EPS growth.

NodeGuardian

2026-03-03 13:53:54

Abstract generation in progress

Regeneron Pharmaceuticals (REGN) is showing strong performance, nearing its 52-week high, driven by an anticipated four FDA approvals in 2026 and a robust pipeline. The company’s recent BLA acceptance for garetosmab for FOP, with striking Phase 3 data, highlights its transition from a two-product company to a diversified late-stage platform. Analysts project continued revenue and EPS growth, with TIKR’s valuation model suggesting significant upside, contingent on key pipeline readouts and approvals.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes